Form 4: Eagle Pharmaceuticals CFO Brian Cahill Reports Stock Award and Tax Withholding

Brian Cahill, CFO of Eagle Pharmaceuticals, reports the acquisition of 3,800 shares of common stock upon vesting of performance stock units and the subsequent withholding of 1,589 shares for tax obligations.

Summary

• On February 27, 2024, Brian Cahill, the Chief Financial Officer of Eagle Pharmaceuticals, acquired 3,800 shares of common stock.
• This acquisition was due to the satisfaction of performance criteria related to performance stock units (PSUs) granted in 2021.
• On the same day, 1,589 shares were disposed of to cover the tax liability associated with the vesting of these PSUs at a price of $6.44 per share.
• Following these transactions, Cahill directly owns 47,958 shares of Eagle Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather reports factual information.

Positives

• The vesting of performance stock units suggests that performance criteria were met, which could be viewed positively.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions in the company's stock. This filing indicates activity by the CFO of Eagle Pharmaceuticals.

Stakeholder Impact

• Shareholders are informed about the CFO's stock transactions, providing transparency into insider activity.

Key Dates

Keywords

Form 4, EGRX, Eagle Pharmaceuticals, Brian Cahill, CFO, Stock, PSU, Performance Stock Units, Tax Withholding, Beneficial Ownership